Pulmatrix, Inc. Stock

PULM

US74584P3010

Biotechnology & Medical Research

Delayed Nasdaq 19:39:03 09/09/2026 +03			5-day change	1st Jan Change
1.560 ^USD	+11.83%		+6.12%	-30.04%

08-13	Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Analysts' recommendations : Pulmatrix, Inc.

30/03/22	HC Wainwright Adjusts Pulmatrix's Price Target to $10 from $5, Keeps Buy Rating	MT
13/04/21	Pulmatrix : HC Wainwright Adjusts Pulmatrix' Price Target to $5 From $10, Keeps Buy Rating	MT

More recommendations

Press Releases : Pulmatrix, Inc.

08-13	Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger	PR
05-15	Pulmatrix Announces First Quarter 2026 Financial Results	PR
04-21	Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger	PR
04-13	PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders	BU
03-26	Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan	PR

More press releases

Managers and Directors : Pulmatrix, Inc.

Manager	Title	Age	Since
Peter Ludlum CEO	Chief Executive Officer	70	20/07/2024

Director	Title	Age	Since
Richard Batycky BRD	Director/Board Member	58	01/11/2019
Christopher Cabell BRD	Director/Board Member	57	23/06/2020
Todd Bazemore BRD	Director/Board Member	55	01/10/2020

More insiders

Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Companyâ€™s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrixâ€™s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
09/09/26	$1.560	+11.83%	265,424
08/09/26	$1.395	+0.36%	7,375
04/09/26	$1.390	+2.21%	20,171
03/09/26	$1.360	-7.48%	20,347
02/09/26	$1.470	-3.61%	18,389

Delayed Quote Nasdaq

More quotes

Market Cap	5.09M 4.38M 4.13M 3.76M 7.04M 485M 7.07M 48.93M 18.91M 247M 19.13M 18.72M 782M	P/E 2024	-2.67x	P/E 2025	-1.58x
Enterprise Value	1.01M 866K 816K 743K 1.39M 95.82M 1.4M 9.67M 3.74M 48.81M 3.78M 3.7M 155M	EV / Sales 2024	2.05x	EV / Sales 2025	-
Free-Float	99.23%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq	PULM	Delayed
CBOE	PULM	Real-time
Boerse Muenchen	2PU	Real-time
Deutsche Boerse AG	2PU	Delayed
Börse Stuttgart	2PU	Delayed
Tradegate	2PU	Real-time

08-13	Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-21	Pulmatrix, Inc. announced that it has received $1 million in funding	CI
04-21	Pulmatrix announces closing of preferred stock transaction as part of planned merger	RE
03-26	Eos SENOLYTIX, Inc. entered into an Agreement and Plan of Merger and Reorganization to acquire Pulmatrix, Inc. in a reverse merger transaction.	CI
03-26	Pulmatrix, Inc. announced that it expects to receive $1 million in funding	CI
03-02	Pulmatrix announces termination of prior planned merger and continues pursuit of alternative merger opportunities	RE
02-28	Cullgen Inc. cancelled the acquisition of Pulmatrix, Inc. in a reverse merger transaction.	CI
02-26	Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-18	Pulmatrix and Cullgen continue to pursue merger	RE
16/10/25	Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
16/10/25	Biopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestment	RE
06/08/25	Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

1 day	+11.83%
1 week	+6.12%
Current month	+6.12%
1 month	-0.64%
3 months	+13.04%
6 months	-23.90%
Current year	-30.04%

1 week	1.36	1.66
1 month	1.36	1.66
Current year	1.16	3.4
1 year	1.16	5.5
3 years	1.16	10.4
5 years	1.16	20.8
10 years	1.16	1,396

Pulmatrix, Inc. Stock

Stocks

PULM

US74584P3010

Biotechnology & Medical Research

Valuation : Pulmatrix, Inc.

Chart: Pulmatrix, Inc.

Latest news : Pulmatrix, Inc.

Analysts' recommendations : Pulmatrix, Inc.

Press Releases : Pulmatrix, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Pulmatrix, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/26/23 A	Michael Higgins	Free	Chairman	2,436	0.0669%
1/26/23 A	Christopher Cabell	Free	Director	1,700	0.0467%
1/26/23 A	Richard Batycky	Free	Director	1,700	0.0467%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PULMATRIX, INC.	+11.83%	+6.12%	-67.30%	-31.58%	5.09M
WUXI APPTEC CO., LTD.	-0.94%	+0.31%	+40.04%	+103.25%	69.19B
ARGENX SE	-0.07%	-3.93%	+32.54%	+75.96%	62.97B
INSMED INCORPORATED	+4.05%	+2.50%	-11.83%	+389.77%	27.27B
BIONTECH SE	-1.00%	-5.93%	-4.35%	-17.21%	24.78B
WUXI BIOLOGICS (CAYMAN) INC.	-0.93%	-1.29%	+25.30%	+16.70%	25.8B
GENMAB A/S	-1.43%	-1.89%	+21.32%	-17.67%	20.11B
PHARMAESSENTIA CORPORATION	-4.27%	+2.67%	+219.02%	+362.48%	18.47B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.43%	-1.80%	-8.64%	+537.09%	14.88B
EXELIXIS, INC.	+0.26%	-1.41%	+50.74%	+162.41%	14.29B
Average	+0.58%	-1.13%	+29.68%	+158.12%	27.78B
Weighted average by Cap.	-0.50%	-0.76%	+36.40%	+141.17%

	2024	2025
Net sales	7.81M 6.72M 6.32M 5.76M 10.78M 743M 10.83M 74.96M 28.97M 378M 29.31M 28.67M 1.2B	-
Net income	-9.56M -8.23M -7.75M -7.06M -13.2M -910M -13.26M -91.79M -35.48M -463M -35.89M -35.11M -1.47B	-5.16M -4.44M -4.18M -3.81M -7.13M -491M -7.16M -49.57M -19.16M -250M -19.38M -18.96M -793M
Net Debt	-9.52M -8.19M -7.71M -7.03M -13.15M -906M -13.2M -91.43M -35.34M -462M -35.75M -34.97M -1.46B	-4.09M -3.52M -3.31M -3.02M -5.65M -389M -5.67M -39.26M -15.17M -198M -15.35M -15.02M -628M